547 related articles for article (PubMed ID: 17145499)
21. Genetic, electrophysiological, and pathological studies on patients with SCN9A-related pain disorders.
Yuan JH; Cheng X; Matsuura E; Higuchi Y; Ando M; Hashiguchi A; Yoshimura A; Nakachi R; Mine J; Taketani T; Maeda K; Kawakami S; Kira R; Tanaka S; Kanai K; Dib-Hajj F; Dib-Hajj SD; Waxman SG; Takashima H
J Peripher Nerv Syst; 2023 Dec; 28(4):597-607. PubMed ID: 37555797
[TBL] [Abstract][Full Text] [Related]
22. A novel mutation in SCN5A, delQKP 1507-1509, causing long QT syndrome: role of Q1507 residue in sodium channel inactivation.
Keller DI; Acharfi S; Delacrétaz E; Benammar N; Rotter M; Pfammatter JP; Fressart V; Guicheney P; Chahine M
J Mol Cell Cardiol; 2003 Dec; 35(12):1513-21. PubMed ID: 14654377
[TBL] [Abstract][Full Text] [Related]
23. Alternative splicing of Na(V)1.7 exon 5 increases the impact of the painful PEPD mutant channel I1461T.
Jarecki BW; Sheets PL; Xiao Y; Jackson JO; Cummins TR
Channels (Austin); 2009; 3(4):259-67. PubMed ID: 19633428
[TBL] [Abstract][Full Text] [Related]
24. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy.
Cummins TR; Dib-Hajj SD; Waxman SG
J Neurosci; 2004 Sep; 24(38):8232-6. PubMed ID: 15385606
[TBL] [Abstract][Full Text] [Related]
25. A sodium channel mutation causing epilepsy in man exhibits subtle defects in fast inactivation and activation in vitro.
Alekov A; Rahman MM; Mitrovic N; Lehmann-Horn F; Lerche H
J Physiol; 2000 Dec; 529 Pt 3(Pt 3):533-9. PubMed ID: 11118488
[TBL] [Abstract][Full Text] [Related]
26. Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.
Natkunarajah J; Atherton D; Elmslie F; Mansour S; Mortimer P
Clin Exp Dermatol; 2009 Dec; 34(8):e640-2. PubMed ID: 19549232
[TBL] [Abstract][Full Text] [Related]
27. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels.
Drenth JP; te Morsche RH; Guillet G; Taieb A; Kirby RL; Jansen JB
J Invest Dermatol; 2005 Jun; 124(6):1333-8. PubMed ID: 15955112
[TBL] [Abstract][Full Text] [Related]
28. Paroxysmal extreme pain disorder (previously familial rectal pain syndrome).
Fertleman CR; Ferrie CD; Aicardi J; Bednarek NA; Eeg-Olofsson O; Elmslie FV; Griesemer DA; Goutières F; Kirkpatrick M; Malmros IN; Pollitzer M; Rossiter M; Roulet-Perez E; Schubert R; Smith VV; Testard H; Wong V; Stephenson JB
Neurology; 2007 Aug; 69(6):586-95. PubMed ID: 17679678
[TBL] [Abstract][Full Text] [Related]
29. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome.
Singh NA; Pappas C; Dahle EJ; Claes LR; Pruess TH; De Jonghe P; Thompson J; Dixon M; Gurnett C; Peiffer A; White HS; Filloux F; Leppert MF
PLoS Genet; 2009 Sep; 5(9):e1000649. PubMed ID: 19763161
[TBL] [Abstract][Full Text] [Related]
30. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders.
Drenth JP; Waxman SG
J Clin Invest; 2007 Dec; 117(12):3603-9. PubMed ID: 18060017
[TBL] [Abstract][Full Text] [Related]
31. State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine.
Wang GK; Calderon J; Wang SY
Mol Pharmacol; 2008 Mar; 73(3):940-8. PubMed ID: 18079277
[TBL] [Abstract][Full Text] [Related]
32. Painful micturition in a small child: an unusual clinical picture of paroxysmal extreme pain disorder.
Meglič A; Perkovič-Benedik M; Trebušak Podkrajšek K; Bertok S
Pediatr Nephrol; 2014 Sep; 29(9):1643-6. PubMed ID: 24817410
[TBL] [Abstract][Full Text] [Related]
33. Sodium channel dysfunction in intractable childhood epilepsy with generalized tonic-clonic seizures.
Rhodes TH; Vanoye CG; Ohmori I; Ogiwara I; Yamakawa K; George AL
J Physiol; 2005 Dec; 569(Pt 2):433-45. PubMed ID: 16210358
[TBL] [Abstract][Full Text] [Related]
34. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors.
Schmalhofer WA; Calhoun J; Burrows R; Bailey T; Kohler MG; Weinglass AB; Kaczorowski GJ; Garcia ML; Koltzenburg M; Priest BT
Mol Pharmacol; 2008 Nov; 74(5):1476-84. PubMed ID: 18728100
[TBL] [Abstract][Full Text] [Related]
35. Genetics and molecular pathophysiology of Na(v)1.7-related pain syndromes.
Dib-Hajj SD; Yang Y; Waxman SG
Adv Genet; 2008; 63():85-110. PubMed ID: 19185186
[TBL] [Abstract][Full Text] [Related]
36. A Novel SCN9A Mutation (F826Y) in Primary Erythromelalgia Alters the Excitability of Nav1.7.
Wu B; Zhang Y; Tang H; Yang M; Long H; Shi G; Tang J; Shi X
Curr Mol Med; 2017; 17(6):450-457. PubMed ID: 28990532
[TBL] [Abstract][Full Text] [Related]
37. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.
Estacion M; Waxman SG; Dib-Hajj SD
Mol Pain; 2010 Jun; 6():35. PubMed ID: 20529343
[TBL] [Abstract][Full Text] [Related]
38. Short-lasting unilateral neuralgiform headache attacks with ispilateral facial flushing is a new variant of paroxysmal extreme pain disorder.
Imai N; Miyake N; Saito Y; Kobayashi E; Ikawa M; Manaka S; Shiina M; Ogata K; Matsumoto N
J Headache Pain; 2015; 16():519. PubMed ID: 25903274
[TBL] [Abstract][Full Text] [Related]
39. Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia.
Cregg R; Laguda B; Werdehausen R; Cox JJ; Linley JE; Ramirez JD; Bodi I; Markiewicz M; Howell KJ; Chen YC; Agnew K; Houlden H; Lunn MP; Bennett DL; Wood JN; Kinali M
Neuromolecular Med; 2013 Jun; 15(2):265-78. PubMed ID: 23292638
[TBL] [Abstract][Full Text] [Related]
40. A sodium channel mutation linked to epilepsy increases ramp and persistent current of Nav1.3 and induces hyperexcitability in hippocampal neurons.
Estacion M; Gasser A; Dib-Hajj SD; Waxman SG
Exp Neurol; 2010 Aug; 224(2):362-8. PubMed ID: 20420834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
